Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets

Wanqiu Chen; Eun Jung Choi; Cameron M. McDougall; Hua Su

doi:10.1007/s12975-014-0343-0

Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets

Wanqiu Chen, Eun Jung Choi, Cameron M. McDougall, Hua Su

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Patients harboring brain arteriovenous malformation (bAVM) are at life-threatening risk of rupture and intracranial hemorrhage (ICH). The pathogenesis of bAVM has not been completely understood. Current treatment options are invasive, and ≈ 20 % of patients are not offered interventional therapy because of excessive treatment risk. There are no specific medical therapies to treat bAVMs. The lack of validated animal models has been an obstacle for testing hypotheses of bAVM pathogenesis and testing new therapies. In this review, we summarize bAVM model development and bAVM pathogenesis and potential therapeutic targets that have been identified during model development.

Original language	English (US)
Pages (from-to)	316-329
Number of pages	14
Journal	Translational Stroke Research
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s12975-014-0343-0
State	Published - Jun 2014
Externally published	Yes

Keywords

Activin-like kinase 1
Angiogenesis
Brain arteriovenous malformation
Conditional knockout
Endoglin
Hereditary hemorrhagic telangiectasia
Mouse models

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s12975-014-0343-0

Cite this

@article{8f5e10ac5206464e95d54530a4bc5c0a,

title = "Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets",

abstract = "Patients harboring brain arteriovenous malformation (bAVM) are at life-threatening risk of rupture and intracranial hemorrhage (ICH). The pathogenesis of bAVM has not been completely understood. Current treatment options are invasive, and ≈ 20 % of patients are not offered interventional therapy because of excessive treatment risk. There are no specific medical therapies to treat bAVMs. The lack of validated animal models has been an obstacle for testing hypotheses of bAVM pathogenesis and testing new therapies. In this review, we summarize bAVM model development and bAVM pathogenesis and potential therapeutic targets that have been identified during model development.",

keywords = "Activin-like kinase 1, Angiogenesis, Brain arteriovenous malformation, Conditional knockout, Endoglin, Hereditary hemorrhagic telangiectasia, Mouse models",

author = "Wanqiu Chen and Choi, {Eun Jung} and McDougall, {Cameron M.} and Hua Su",

note = "Funding Information: Acknowledgments We thank Voltaire Gungab for assistance with manuscript preparation and members of the UCSF BAVM Study Project (http://avm.ucsf.edu) for their support. The principal investigator, Hua Su, is supported by grants from the National Institutes of Health (R01 NS027713 and P01 NS044155).",

year = "2014",

month = jun,

doi = "10.1007/s12975-014-0343-0",

language = "English (US)",

volume = "5",

pages = "316--329",

journal = "Translational Stroke Research",

issn = "1868-4483",

publisher = "Springer US",

number = "3",

}

TY - JOUR

T1 - Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets

AU - Chen, Wanqiu

AU - Choi, Eun Jung

AU - McDougall, Cameron M.

AU - Su, Hua

N1 - Funding Information: Acknowledgments We thank Voltaire Gungab for assistance with manuscript preparation and members of the UCSF BAVM Study Project (http://avm.ucsf.edu) for their support. The principal investigator, Hua Su, is supported by grants from the National Institutes of Health (R01 NS027713 and P01 NS044155).

PY - 2014/6

Y1 - 2014/6

N2 - Patients harboring brain arteriovenous malformation (bAVM) are at life-threatening risk of rupture and intracranial hemorrhage (ICH). The pathogenesis of bAVM has not been completely understood. Current treatment options are invasive, and ≈ 20 % of patients are not offered interventional therapy because of excessive treatment risk. There are no specific medical therapies to treat bAVMs. The lack of validated animal models has been an obstacle for testing hypotheses of bAVM pathogenesis and testing new therapies. In this review, we summarize bAVM model development and bAVM pathogenesis and potential therapeutic targets that have been identified during model development.

AB - Patients harboring brain arteriovenous malformation (bAVM) are at life-threatening risk of rupture and intracranial hemorrhage (ICH). The pathogenesis of bAVM has not been completely understood. Current treatment options are invasive, and ≈ 20 % of patients are not offered interventional therapy because of excessive treatment risk. There are no specific medical therapies to treat bAVMs. The lack of validated animal models has been an obstacle for testing hypotheses of bAVM pathogenesis and testing new therapies. In this review, we summarize bAVM model development and bAVM pathogenesis and potential therapeutic targets that have been identified during model development.

KW - Activin-like kinase 1

KW - Angiogenesis

KW - Brain arteriovenous malformation

KW - Conditional knockout

KW - Endoglin

KW - Hereditary hemorrhagic telangiectasia

KW - Mouse models

UR - http://www.scopus.com/inward/record.url?scp=84901192304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901192304&partnerID=8YFLogxK

U2 - 10.1007/s12975-014-0343-0

DO - 10.1007/s12975-014-0343-0

M3 - Review article

C2 - 24723256

AN - SCOPUS:84901192304

SN - 1868-4483

VL - 5

SP - 316

EP - 329

JO - Translational Stroke Research

JF - Translational Stroke Research

IS - 3

ER -

Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this